MEDICINAL CANNABIS

Today Creso Pharma (ASX: CPH | OTC: COPHF) announced its plans to merge with a Canadian listed psychedelics company called Red Light Holland.

The US OTC listing gives Creso Pharma Ltd (ASX: CPH) greater exposure to a deeper capital market as well as greater access and liquidity for North American investors. Further to this, it provide additional opportunities to attract institutional and retail investors and for CPH to expand its investor base in the US.

Neurotech International Ltd (ASX: NTI) has begun its first clinical trials on children aged between 5 and 17 years with Autism Spectrum Disorder (ASD) for its unique cannabis strain.

There were several highlights to come out of the quarterly report released by Creso Pharma (ASX: CPH) today. CPH is enjoying a sustained run this year with revenues up 237% in the lead up to its US listing, which is expected to occur in the coming weeks.

Medicinal cannabis, CBD and hemp healthcare products company, Bod Australia Limited (ASX: BDA) has provided its shareholders an update for the Q3FY2021 quarter, ended 31 March 2021.

Creso Pharma’s (ASX: CPH) pending acquisition of Halucenex Life Sciences should prove to be an astute move, with Halucenex continuing to rapidly move towards its goal of developing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets.

Creso Pharma (ASX: CPH) has received firm commitments to raise $18M, a sum that significantly shores up its balance sheet. CPH will use the funds to progress a number of value accretive opportunities including Phase II and Phase III clinical trial initiatives with target acquisition company Halucenex Life Sciences Inc.

Creso Pharma (ASX: CPH) today announced it is listing on the OTC market in the USA. Listing on the OTC is expected to unlock significant shareholder value and provides CPH with access to one of the largest investment markets in the world at nominal cost.

Bod Australia (ASX: BDA) is a cannabis centric healthcare company, with well-branded premium, proven and trusted products within two distinct verticals: Medical Cannabis and CBD and Hemp Consumer products.

Neurotech International Limited (ASX: NTI) has announced a strategic cultivation partnership with CannaPacific Limited to grow and maintain genetic stock and assist in the development of elite varietal strains through their exclusive licencing agreement.

Following the successful in vitro findings, Neurotech (ASX: NTI) has begun designing a phase I/II study to assess the safety and efficacy of the novel NTI/Dolce strain in a paediatric population.

Today Creso Pharma (ASX: CPH) reported new and follow up Purchase Orders for its animal health medicinal cannabis products totalling over A$345,000.

Neurotech International Ltd (ASX: NTI) is focused on the clinical applications of unique cannabis strains to treat neurological disorders such as autism and is set to commence human clinical trials early in 2021.

Creso Pharma Limited (ASX:CPH, FRA:1X8) has today announced obtainment of an exclusive Heads of Agreement with leading natural, sustainable health and lifestyle brand supplier Martin & Pleasance Pty Ltd.

The TGA has recommended that CBD products be down-scheduled to schedule 3 medicines in Australia, allowing OTC sales, which should benefit Creso Pharma (ASX: CPH).

Joe Biden announced that Kamala Harris is his pick for Vice President, should he win the upcoming US Presidential election in November. But what could a Biden/Harris ticket mean for cannabis legalization?

Despite the pro-cannabis atmosphere in 2019 during the Democrat primaries and Biden's and Harris's evolving stances on cannabis, there were no comments on cannabis legalization in the 2020 DNC.

Here to speak with Finfeed today about the ups and downs of the cannabis industry, cannabis in Canada and what he sees is the future of the cannabis industry is COO and director of Embark Health, Mike Curtis.